RECIST and WHO Criteria Evaluation of Cervical, Thoracic and Abdominal Lymph Nodes in Patients with Malignant Lymphoma: Manual versus Semi-Automated Measurement on Standard MDCT Slices

Keil, Sebastian; Behrendt, Florian F.; Stanzel, S.; Suehling, Michael; Jost, Edgar; Mühlenbruch, Georg; Mahnken, Andreas H.; Günther, Rolf W.; Das, Marco

doi:10.1055/s-0028-1109509

Cited by 14 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such a discriminating technique may also be applied to liver lesions [15], [16]. The validation cohort was studied solely with semi-automated measurements, since they demonstrated robust correlation with manual measurements in our training cohort, which is consistent with literature data ( Figure S1 ) [14]–[17].…”

Section: Methodssupporting

confidence: 82%

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Schiavon

Ruggiero²,

Schöffski³

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

BackgroundAssessment of tumor size changes is crucial in clinical trials and patient care. We compared imatinib-induced volume changes of liver metastases (LM) from gastro-intestinal stromal tumors (GIST) to RECIST and Choi criteria and their association with overall survival (OS).MethodsLM from 84 GIST patients (training and validation set) were evaluated using manual and semi-automated Computed Tomography measurements at baseline, after 3, 6 and 12 months of imatinib. The ability of uni-dimensional (1D) and three-dimensional (3D) measurements to detect size changes (increase/decrease) ≥20% was evaluated. Volumetric response cut-offs were derived from minimally relevant changes (+20/−30%) by RECIST, considering lesions as spherical or ellipsoidal.Results3D measurements detected size changes ≥20% more frequently than 1D at every time-point (P≤0.008). 3D and Choi criteria registered more responses than RECIST at 3 and 6 months for 3D-spheres (P≤0.03) and at all time-points for 3D-ellipsoids and Choi criteria (P<0.001). Progressive disease by 3D criteria seems to better correlate to OS at late time-points than other criteria.ConclusionVolume criteria (especially ellipsoids) classify a higher number of patients as imatinib-responders than RECIST. Volume discriminates size changes better than diameter in GIST and constitutes a feasible and robust method to evaluate response and predict patient benefit.

show abstract

Section: Methodssupporting

confidence: 82%

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Schiavon

Ruggiero²,

Schöffski³

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…6 Extranodal disease positivity was considered with increased organ size, abnormal contrast enhancement, soft tissue nodules or masses, and bone changes. An independent radiologist with broad experience in CT interpreted the ceCT64 examinations.…”

Section: Methodsmentioning

confidence: 99%

“…5,6 Hodgkin lymphoma, DLBCL, and FL are FDG avid. 7–9 FDG PET/CT modifies lymphoma stage in between 14% and 59% of patients when compared with CT or FDG PET without CT. 10–18 There are few high-evidence-level prospective studies validating the use of PET/CT in the treatment of lymphoma.…”

mentioning

confidence: 99%

Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi–Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma

León¹,

Delgado-Bolton²,

Val³

et al. 2017

Clinical Nuclear Medicine

View full text Add to dashboard Cite

ObjectivesTo compare staging correctness between contrast-enhanced FDG PET/ceCT and 64-slice multi–detector-row CT (ceCT64) for initial staging and response evaluation at the end of treatment (EOT) in patients with Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), and follicular lymphoma.MethodsThis prospective study compared initial staging and response evaluation at EOT. One hundred eighty-one patients were randomly assigned to either ceCT64 or FDG PET/ceCT. A nuclear medicine physician and a radiologist read FDG PET/ceCT scans independently and achieved post hoc consensus, whereas another independent radiologist interpreted ceCT64 separately. The reference standard included all clinical information, all tests, and follow-up. Ethics committees of the participating centers approved the study, and all participants provided written consent.ResultsNinety-one patients were randomized to ceCT64 and 90 to FDG PET/ceCT; 72 had Hodgkin lymphoma, 72 had DLBCL, and 37 had follicular lymphoma. There was excellent correlation between the reference standard and initial staging for both FDG PET/ceCT (κ = 0.96) and ceCT64 (κ = 0.84), although evaluation of the response at EOT was excellent only for FDG PET/ceCT (κ = 0.91).ConclusionsOur study demonstrated satisfactory agreement between FDG PET/ceCT (κ = 0.96) and ceCT64 (κ = 0.84) in initial staging compared with the reference standard (P = 0.16). Response evaluation at EOT with FDG PET/ceCT (κ = 0.91) was superior compared with ceCT64 (κ = 0.307) (P < 0.001).

show abstract

“…Software for volumetric analysis of lymph node metastases has become available only recently [9][10][11]. In comparison to lung nodules, volumetric analysis of lymph nodes is considered more challenging, as lymph node metastases are often irregular with heterogenous contrast enhancement, are often adjacent to structures of similar density and tend to fuse in the case of tumour growth.…”

Section: Introductionmentioning

confidence: 99%

Semi-automated volumetric analysis of lymph node metastases during follow-up—initial results

et al. 2010

View full text Add to dashboard Cite

show abstract

RECIST and WHO Criteria Evaluation of Cervical, Thoracic and Abdominal Lymph Nodes in Patients with Malignant Lymphoma: Manual versus Semi-Automated Measurement on Standard MDCT Slices

Abstract: Semi-automated measurement of cervical, thoracic and abdominal lymph nodes showed valid results on standard axial reconstructions compared to manual quantification with the limitation of a high false segmentation rate in thoracic lymph nodes.

Cited by 14 publications

References 20 publications

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi–Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma

Semi-automated volumetric analysis of lymph node metastases during follow-up—initial results

Contact Info

Product

Resources

About